Inhaled PYY(3–36) dry-powder formulation for appetite suppression

Peptide YY3–36 [PYY(3–36)] has shown efficacy in appetite suppression when dosed by injection modalities (intraperitoneal (IP)/subcutaneous). Transitioning to needle-free delivery, towards inhalation, often utilizes systemic pharmacokinetics as a key endpoint to compare different delivery methods and doses. Systemic pharmacokinetics were evaluated for PYY3–36 when delivered by IP, subcutaneous, and inhalation, the systemic pharmacokinetics were then used to select doses in an appetite suppression pharmacodynamic study.

We use cookies on Capsugel.com. Cookies allow us to give you the best browsing experience and helps us to understand how you use our site. You can disable cookies but parts of our site will not work. Please read our Cookie Policy for information about which cookies we use and the information we collect. By continuing to use this site, you agree that we may store and access cookies on your device.